Evoke Pharma, Inc. (EVOK)
EVOK moved a median of 0.00% 30 minutes after news, and -0.05% by the close. How EVOK actually reacts to news — the realized, point-in-time move the market made, measured across 212 labeled events over the last three years with zero look-ahead.
EVOK’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 26% | 124 |
| 30-min | 0.00% | 34% | 160 |
| 60-min | -0.07% | 36% | 165 |
| to close | -0.05% | 47% | 172 |
| Middle 50% of EVOK reactions | -1.57% to +0.39% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 212 |
Half of all Evoke Pharma, Inc. news events land between -1.57% and +0.39% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when EVOK moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EVOK's baseline. Nothing else.
Recent EVOK events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Evoke Pharma Inc | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Evoke Pharma Inc | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Evoke Pharma and QOL Medical Announce Expiration of Tender Offer | Press release | PR Newswire | — | — | |
| Form 8-K Evoke Pharma Inc For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Evoke Pharma Inc | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Evoke Pharma Inc | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Halper Sadeh LLC Encourages EVOK, FSFG, BRY Shareholders to Contact the Firm to Discuss Their Rights | Press release | GlobeNewswire | +0.00% | +0.09% | |
| Halper Sadeh LLC Encourages AXTA, COMP, EVOK, JTAI Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | — | -0.09% | |
| Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.18% | — | |
| Form 10-Q Evoke Pharma Inc For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.18% | — | |
| Form 8-K Evoke Pharma Inc For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | — | |
| Halper Sadeh LLC Encourages HBAN, FFWM, EVOK Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | — | +0.21% | |
| EVOK Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Evoke Pharma, Inc. is Fair to Shareholders | Press release | Business Wire | -0.01% | -0.95% | |
| Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical | Press release | GlobeNewswire | -0.19% | -0.37% | |
| Form 8-K Evoke Pharma Inc For: Oct 29 | SEC filing · Form 8-K | SEC EDGAR | -0.19% | -0.37% | |
| Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship | Press release | GlobeNewswire | -1.95% | +2.66% | |
| Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book | Press release | GlobeNewswire | +3.22% | -2.76% | |
| Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.65% | +6.42% | |
| Form 10-Q Evoke Pharma Inc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.65% | +6.42% | |
| Form 8-K Evoke Pharma Inc For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -1.65% | +6.42% | |
| Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038 | Press release | GlobeNewswire | -1.62% | +2.52% | |
| Form 8-K Evoke Pharma Inc For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -1.62% | +2.52% | |
| Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 | Press release | GlobeNewswire | -4.51% | -18.05% | |
| Form 8-K Evoke Pharma Inc For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | -4.51% | -18.05% | |
| Form 8-K Evoke Pharma Inc For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.01% | |
| Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | — | +0.32% | |
| Form 10-Q Evoke Pharma Inc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | +0.32% | |
| Form 8-K Evoke Pharma Inc For: May 13 | SEC filing · Form 8-K | SEC EDGAR | — | +0.32% | |
| Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025 | Press release | GlobeNewswire | — | +4.31% | |
| Form ARS Evoke Pharma Inc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.32% | -3.08% | |
| Form DEF 14A Evoke Pharma Inc For: May 21 | SEC filing · Form DEF | SEC EDGAR | -1.32% | -3.08% | |
| Form DEFA14A Evoke Pharma Inc | SEC filing · Form DEFA14A | SEC EDGAR | -1.32% | -3.08% | |
| Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.18% | -0.26% | |
| Form 10-K Evoke Pharma Inc For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.18% | -0.26% | |
| Form 8-K Evoke Pharma Inc For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | -0.26% | |
| Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025 | Press release | GlobeNewswire | +0.00% | +2.12% | |
| Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors | Press release | GlobeNewswire | — | +0.42% | |
| Form 8-K Evoke Pharma Inc For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | — | +0.42% | |
| Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends | Press release | GlobeNewswire | +0.66% | +20.39% | |
| Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® | Press release | GlobeNewswire | +5.35% | -2.09% | |
| Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results | Press release | GlobeNewswire | -1.40% | -3.75% | |
| Form 10-Q Evoke Pharma Inc For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.40% | -3.75% | |
| Form 8-K Evoke Pharma Inc For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | -1.40% | -3.75% | |
| Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI® | Press release | GlobeNewswire | -9.48% | -36.67% | |
| Form 8-K Evoke Pharma Inc For: Oct 28 | SEC filing · Form 8-K | SEC EDGAR | -9.48% | -36.67% | |
| Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting | Press release | GlobeNewswire | — | -4.65% | |
| Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors | Press release | GlobeNewswire | — | -3.40% | |
| Form 8-K Evoke Pharma Inc For: Oct 18 | SEC filing · Form 8-K | SEC EDGAR | — | -3.40% | |
| Form 8-K Evoke Pharma Inc For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.23% | |
| Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion | Press release | GlobeNewswire | +0.00% | -0.61% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EVOK section they belong to.
Where else EVOK is measured.
EVOK earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Evogene Ltd. - Ordinary Shares (EVGN) | 213 | -0.48% | 38% |
| AMARANTUS BIOSCIENCE HLDG (AMBS) | 212 | 0.00% | 43% |
| PRECISION THERAPEUTICS INC COMMON (AIPT) | 211 | 0.00% | 46% |
| Amarin Corporation plc - American Depositary Shares (AMRN) | 211 | +0.30% | 55% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Evoke Pharma, Inc.'s median reaction calculated?
Every labeled EVOK news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 212 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 34% of EVOK's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EVOK's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.